Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Marta Simone et al.|JAMA Neurology|2021Cited by 62
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomáš Kalinčík, John A. Snowden, Andrew Grigg et al.|JAMA Neurology|2023Cited by 55
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout durationDiana Ferraro, Carlo Pozzilli, Pietro Iaffaldano et al.|Journal of Neurology|2021Cited by 10
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders RegisterPaola Mosconi, Marinella Clerico, Tommaso Guerra et al.|Neurological Sciences|2023Cited by 9
Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders registerRoberto Bergamaschi, Maura Danni, Ettore Beghi et al.|Neurological Sciences|2022Cited by 4